Gemcitabine DNA Synthesis Inhibitor, 50mg and 1 more item

The University of Virginia awarded contract A207_PO-0446730-V3 to Selleck Chem LLC on August 8, 2026, for the procurement of pharmaceutical research compounds. The contract, valued at $384, encompasses the delivery of two distinct line items to the buyer. The first line item consists of 147 units of Gemcitabine, a deoxyribonucleic acid (DNA) synthesis inhibitor with a concentration of 50 milligrams, priced at $1 per unit. The second line item comprises 237 units of MRTX1133, a Kirsten rat sarcoma (KRAS)-G12D inhibitor with a concentration of 10 millimolar, also priced at $1 per unit.

This contract represents a transactional procurement of research-grade pharmaceutical compounds by the University of Virginia, a Virginia-based institution of higher education. The modest contract value and unit pricing structure indicate this is a specialized purchase of laboratory reagents for research purposes. Both compounds represent targeted oncology research materials, with Gemcitabine functioning as a nucleoside analog utilized in cancer therapy research and MRTX1133 representing a targeted inhibitor of a specific KRAS mutation prevalent in cancer biology studies. No specific period of performance or county designation was provided in the contract documentation.